CharlestonPharma LLC

About

CharlestonPharma LLC operates as a specialized pharmaceutical research and development company based in Charleston, South Carolina, focused on advancing innovative cancer treatment solutions. The company has distinguished itself in the healthcare industry through its development of cutting-edge anti-nucleolin antibodies designed specifically for cancer therapy applications. The organization centers its research efforts on developing monoclonal antibody treatments, with their lead product CP101.2C8 representing a breakthrough approach to cancer treatment. This proprietary antibody targets nucleolin transporter proteins located on tumor cell surfaces, utilizing a unique mechanism that destabilizes oncogenic messenger RNAs and induces programmed cell death in cancer cells. Clinical research demonstrates that their antibody technology exhibits high potency against diverse tumor cell lines, positioning CharlestonPharma as an innovative force in targeted cancer therapeutics. CharlestonPharma maintains rigorous research standards while developing these advanced pharmaceutical products, contributing valuable research to the broader oncology community through published studies and collaborative partnerships. The company operates from Charleston, leveraging the regions growing biotechnology infrastructure and research capabilities. Their specialized focus on nucleolin-targeting antibody development represents a distinctive approach within pharmaceutical manufacturing, offering potential therapeutic benefits for patients with various cancer types. CharlestonPharma continues advancing their research pipeline while maintaining commitment to developing effective, targeted cancer treatments that address significant unmet medical needs in oncology care.